|
US2004071762A1
|
|
Diagnostic test for schizophrenia, using niacin
|
|
AU9723801A
|
|
Fatty acid treatment
|
|
CA2403912A1
|
|
Polynucleotides that control delta-6-desaturase genes and methods for identifying compounds for modulating delta-6-desaturase
|
|
CA2301158A1
|
|
Screening methods for compounds useful for modulating lipid metabolism in disease
|
|
GB0005855D0
|
|
Compounds for pdt
|
|
GB0001455D0
|
|
Porphyrins and related compounds
|
|
GB9908176D0
|
|
Cancer treatment
|
|
GB9901265D0
|
|
Organic acid derivatives
|
|
CA2245202A1
|
|
Tumour localising photosensitising compounds
|
|
NZ501762A
|
|
Satiety product comprising triglyceride oils and an emulsifier
|
|
GB9811622D0
|
|
Drug formulation
|
|
AU7222598A
|
|
Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
|
|
GB9804363D0
|
|
Preparation of esters
|
|
GB9804361D0
|
|
Cancer treatment
|
|
ZA9801668B
|
|
Presentation of fatty acids
|
|
GB9804144D0
|
|
Preparation of esters
|
|
GB9800116D0
|
|
Photoreactive compounds
|
|
GB9722521D0
|
|
Plant transformants
|
|
ZA9709411B
|
|
The use of lithium compounds for combatting human papilloma virus infections.
|
|
KR20000049016A
|
|
Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
|
